

The Importance of Early Recognition of Tay–Sachs and Sandhoff Disease



References

- Bembi B, Marchetti F, Guerci VI, et al. Substrate reduction therapy in the infantile form of Tay-Sachs disease. *Neurology*. 2006;66(2):278-280.
- Bley AE, Giannikopoulos OA, Hayden D, Kubilus K, Tiftt CJ, Eichler FS. Natural history of infantile G(M2) gangliosidosis. *Pediatrics*. 2011;128(5):e1233-e1241.
- Breiden B, Sandhoff K. Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease. *Int J Mol Sci*. 2020;21(7):2566.
- Clarke JT, Mahuran DJ, Sathe S, et al. An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants). *Mol Genet Metab*. 2011;102(1):6-12.
- Isaksson A, Hultberg B. Serum beta-hexosaminidase isoenzymes are precursor forms. *Scand J Clin Lab Invest*. 1995;55(5):433-440. doi:org/10.3109/00365519509104983
- Jarnes-Utz JR, Kim S, King K, et al. Infantile gangliosidoses: Mapping a timeline of clinical changes. *Mol Genet Metab*. 2017;121(2):170-179.
- Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldoxynojirimycin. *Proc Natl. Acad. Sci USA*. 1999;96(11):6388-6393.
- Johnson WG, Desnick JL, Long DM, et al. Intravenous injection of purified hexosaminidase A into a patient with Tay-Sachs disease. *Birth Defects Orig Artic Ser*. 1973;9(2):120-124.
- Kaya E, Smith DA, Smith C, et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. *Brain Commun*. 2020;3(1):fcaa148.
- King KE, Kim S, Whitley CB, Jarnes-Utz JR. The juvenile gangliosidoses: A timeline of clinical change. *Mol Genet Metab Rep*. 2020;25:100676.
- Leal AF, Benincore-Florez E, Solana-Galarza D, et al. GM2-gangliosidoses: Clinical features, pathophysiological aspects, and current therapies. *Int J Mol Sci*. 2020;21(17):6213.
- Lopez PH, Schnaar RL. Gangliosides in cell recognition and membrane protein regulation. *Curr Opin Struct Biol*. 2009;19(5):549-557.
- Lyn N, Pulikottil-Jacob R, Rochmann C, et al. Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases. *Orphanet J Rare Dis*. 2020;15(1):92.
- Maegawa GHB, van Giersbergen PLM, Yang S, et al. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis. *Mol Genet Metab*. 2009;97(4):284-291.
- Marshall J, Sun Y, Bangari DS, et al. CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease. *Mol Ther*. 2016;24(6):1019-1029.
- Neudorfer O, Pastores GM, Zeng BJ, Gianutsos J, Zaroff CM, Kolodny EH. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. *Genet Med*. 2005;7(2):119-123.
- Osher E, Fattal-Valevski A, Sagie L, et al. Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study. *Orphanet J Rare Dis*. 2015;10:45.
- Ou L, Przybilla MJ, Tabaran AF, et al. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases. *Gene Ther*. 2020;27(5):226-236.
- Azafaros. Our lead programme. Published 2023. Accessed May 29, 2023. <https://www.azafaros.com/lead-program-drug-discovery-program/>

The Importance of Early Recognition of Tay–Sachs and Sandhoff Disease



- Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. *Clin Pharmacol Drug Dev.* 2021;10:86-98.
- Picache JA, Zheng W, Chen CZ. Therapeutic strategies for Tay-Sachs disease. *Front Pharmacol.* 2022;13:906647.
- Pluvia Biotech. Our science. Published 2023. Accessed June 6, 2023. <https://pluviabiotech.com>
- Cleveland Clinic. Sandhoff disease. Published July 7, 2021. Accessed July 9, 2023. <https://my.clevelandclinic.org/health/articles/6086-sandhoff-disease>
- Sandhoff K, Harzer K. Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis. *J Neurosci.* 2013;33(25):10195-10208.
- Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. *Genet Med.* 2009;11(6):425-433.
- Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: Physiology, pathophysiology and therapeutic applications. *Front Neurosci.* 2020;14:572965.
- Toro C, Zainab M, Tiffet CL. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment. *Neurosci Lett.* 21;764:136195.
- Yu RK, Tsai Y, Ariga T, Yanagisawa M. Structures, biosynthesis, and functions of gangliosides—an overview. *J Oleo Sci.* 2011;60(10):537-544.